Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Total Liabilities: 2020-2024

Historic Total Liabilities for Relay Therapeutics (RLAY) over the last 5 years, with Dec 2024 value amounting to $93.5 million.

  • Relay Therapeutics' Total Liabilities fell 31.74% to $62.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.3 million, marking a year-over-year decrease of 31.74%. This contributed to the annual value of $93.5 million for FY2024, which is 1.66% up from last year.
  • Per Relay Therapeutics' latest filing, its Total Liabilities stood at $93.5 million for FY2024, which was up 1.66% from $92.0 million recorded in FY2023.
  • In the past 5 years, Relay Therapeutics' Total Liabilities registered a high of $149.6 million during FY2022, and its lowest value of $36.5 million during FY2020.
  • Moreover, its 3-year median value for Total Liabilities was $93.5 million (2024), whereas its average is $111.7 million.
  • As far as peak fluctuations go, Relay Therapeutics' Total Liabilities soared by 202.81% in 2021, and later tumbled by 38.50% in 2023.
  • Relay Therapeutics' Total Liabilities (Yearly) stood at $36.5 million in 2020, then soared by 202.81% to $110.6 million in 2021, then spiked by 35.18% to $149.6 million in 2022, then tumbled by 38.50% to $92.0 million in 2023, then rose by 1.66% to $93.5 million in 2024.